Type 2 diabetes
Conditions
Interventions
None listed
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with type 2 diabetes who were hospitalized in Hokkaido University Hospital from February 2020 to December 2021. 2) 20-80 years old 3) HbA1c >= 6.5% 4) Patients who have been treated with combination therapy using DPP-4 inhibitor and insulin degludec (<=16 unit/day) for more than 3 days with stable blood glucose condition 5) Treatment with degludec/liraglutide will be appropriate to achieve preferable glycemic control 6) Agreement to participate to this study
Exclusion criteria
Exclusion criteria: 1) History of anaphylaxis of insulin degludec or liraglutide 2) Unstable glycemic control 3) Severe hepatic dysfunction, renal dysfunction 4) Pregnancy 5) Diabetic ketosis, coma and precoma 6) Serious infection, pre-or post-surgery 7) Poor adherence to dietary therapy 8) Poor insulin secretion 9) Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of mean amplitude of glycemic excursions (MAGE) before and after switching of treatment | — |
Countries
Japan
Contacts
Public ContactHiroshi Nomoto
Hokkaido University Hospital Department of Internal Medicine II
Outcome results
None listed